Skip to content
ClinCalc Pro
Menu
Reflux suppressant (alginate raft + antacid)

Sodium alginate with calcium carbonate and sodium bicarbonate

Brand names: Gaviscon Advance, Peptac

A compound alginate-antacid raft-forming preparation used for the symptomatic relief of gastro-oesophageal reflux, heartburn and acid regurgitation, including in pregnancy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

On contact with gastric acid the alginate precipitates into a viscous gel raft that floats on the stomach contents and physically impedes reflux, while the carbonate components neutralise acid and generate the gas that buoys the raft.

Prescribing in practice

  • Each dose carries a notable sodium load from the bicarbonate and alginate, so use with caution in patients on a restricted-sodium diet or with heart failure, hypertension or significant renal impairment.
  • Take after meals and at bedtime, and separate dosing from other oral medicines as the raft and the antacid component can reduce absorption of concurrently administered drugs.
  • Persistent, worsening or alarm symptoms (dysphagia, weight loss, gastrointestinal bleeding) warrant investigation rather than continued self-treatment.

Monitoring

Routine laboratory monitoring is not required, but review symptom control and reconsider the diagnosis if reflux symptoms persist despite regular use.

Counselling the patient

  • Take after meals and at bedtime for best effect on reflux.
  • Leave a gap before or after other tablets to avoid reducing their absorption.
  • See your prescriber if symptoms persist, worsen, or you have difficulty swallowing.

Evidence & guidelines

Raft-forming alginate preparations are recommended in NICE guidance as an option for the symptomatic management of dyspepsia and gastro-oesophageal reflux.

Reference: NICE CG184; RCOG; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.